Co-Diagnostics, Inc.

Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum and therefore was unable to transact business at the Annual Meeting, nor at the adjournment of the Annual Meeting held on September 24, 2026. As a result, the Annual Meeting was adjourned to September 30, 2026. However, the Company again did not achieve a quorum and therefore was unable to transact business at the meeting. Pursuant to the Company’s bylaws, if a quorum is not present or represented at any meeting of the stockholders, the chairperson of the meeting has the power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present or represented. Accordingly, the Annual Meeting was again adjourned to October 14, 2026, at 9:30 a.m. Mountain Time. The reconvened meeting will be held at the Company’s offices located at 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109. At the adjourned Annual Meeting on October 14, 2026, stockholders will be deemed to be present in person and vote at such adjourned meeting in the same manner as disclosed in the definitive proxy statement the Company filed with the Securities and Exchange Commission on July 21, 2026. Valid proxies submitted prior to the reconvened Annual Meeting will continue to be valid for the Annual Meeting, unless properly changed or revoked prior to votes being taken at such reconvened Annual Meeting.